Inselspital, Bern University Hospital / University Cancer Center Inselspital
Bern's university hospital, a high-volume radioligand therapy centre and home to the Bern Center for Precision Medicine and the SAKK trial group.
The University Cancer Center Inselspital coordinates cancer care at Switzerland's capital university hospital. Its nuclear medicine department under Axel Rominger is one of Europe's largest PSMA and somatostatin-receptor radioligand therapy centres with a strong dosimetry programme, and Mark Rubin, co-discoverer of the TMPRSS2-ERG fusion in prostate cancer, directs the Department for BioMedical Research and the Bern Center for Precision Medicine. The hospital runs neuro-oncology and neurosurgery, thoracic and gastrointestinal surgery, haematology and CAR-T, and is a lead site for the Swiss Group for Clinical Cancer Research (SAKK), whose coordinating centre is in Bern. The Insel Gruppe covers a large catchment across the Bernese region.
- Radioligand therapy and dosimetry
- Bern Center for Precision Medicine
- Prostate cancer genomics
- Neuro-oncology
- SAKK trials
Pages like this
not linked directly; found by shared links- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Dosimetry, Lutetium-177 dotatate, Theranostics, Somatostatin receptor 2.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares Lutetium-177 dotatate, Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- CompanyClarity Pharmaceuticals
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET, Neuroendocrine tumours.
- InstitutionErasmus MC Cancer Institute
Shares Lutetium-177 dotatate, Theranostics, Somatostatin receptor 2, Neuroendocrine tumours.
- InstitutionHolden Comprehensive Cancer Center, University of Iowa
Shares Lutetium-177 dotatate, Somatostatin receptor 2, Neuroendocrine tumours, Radioligand therapy (beta emitters).
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET.